ArticleBMC gastroenterology2025
Effect of Allostatic Load on hepatic steatosis and fatty liver-associated liver fibrosis.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Allostatic Load Index (ALI), as a comprehensive biomarker for assessing the body’s chronic stress response, has been widely used in quantitative studies of the physiological mechanisms of stress. In this study, we systematically investigated the relationship between ALI and hepatic steatosis and fibrosis through cross-sectional analysis.
methodsThis study was based on the National Health and Nutrition Examination Survey (NHANES) 2017 - March 2020 dataset. The ALI was categorized into three grades of ≤ 1, 2 and ≥ 3, and after two types of missing data of covariates were processed by the deletion method and multiple interpolation, multiple linear regression and subgroup models were constructed to assess the association between ALI and hepatic steatosis / fibrosis. The mediator model was used to validate the mediating effects of hepatic steatosis, Neutrophil-to-Lymphocyte Ratio(NLR) and alcohol consumption in the ALI-hepatic fibrosis pathway.
resultsThe study ultimately included 5,992 eligible participants, including 2,674 patients with fatty liver and 663 patients with liver fibrosis.In the fatty liver subgroup, the percentages of ALI ≤ 1, ALI = 2, and ALI ≥ 3 were 23.98%, 33.35%, and 42.67%; in the hepatic fibrosis subgroup, the above percentages were 20.11%, 26.77%, and 53.12%.Elevated ALI (≥ 3) was independently associated with higher age, lower education level, comorbidities, NLR, DII and liver-related parameters (CAP, LSM, AST) (p < 0.05).In the general sampled NHANES population, individuals with ALI ≥ 3 had 1.410× higher adjusted hepatic steatosis prevalence (Odds Ratio, 1.410(1.251–1.584)) and 1.114× higher adjusted liver fibrosis prevalence (Odds Ratio, 1.114(1.066–1.164)) compared with those with ALI ≤ 1. In a sensitivity analysis based on multiple interpolated data, a multifactorial corrected model showed that an ALI ≥ 3 was associated with a 40% increased risk of hepatic steatosis and a 10% increased risk of hepatic fibrosis (p < 0.05). Subgroup analyses showed the association between ALI = 2 and risk of fatty liver was not statistically significant in those ≥ 65 years of age (p = 0.066), whereas ALI ≥ 2 still maintained a significant association in the other subgroup (p < 0.05); ALI ≥ 3 showed a significant association with the risk of liver fibrosis in comorbidities, gender subgroups, light alcohol consumption, Non-Hispanic white, Other Race (p < 0.05). The total effect of ALI on liver fibrosis was 0.063 (p < 0.001), of which 22.6% was mediated by CAP (indirect effect: 0.014, p < 0.001) and direct effect 0.049 (p = 0.014); NLR and alcohol consumption did not show significant mediating effects (p > 0.05).
conclusionALI is associated with liver outcomes, and systemic stress responses exacerbate the progression of liver disease. Assessing ALI is beneficial for managing fatty liver disease and hepatic fibrosis; however, further longitudinal studies are required to establish causality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.